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This study is aimed at evaluating the immunogenicity of two inactivated (mono- and polyvalent) 
vaccines containing bovine virus diarrhea virus (BVDV) reference and field strains. Three experimental 
groups were formed: 10 calves vaccinated twice (days 1 and 28) subcutaneously (s/c) with 2 ml of 
inactivated polyvalent vaccine per animal (Group 1); 10 calves vaccinated twice (days 1 and 28) 
subcutaneously (s/c) with 2 ml of inactivated monovalent vaccine per animal (Group 2) and 9 
unvaccinated calves (Control, Group C). Blood sera were obtained from immunized animals (standard 
procedure: on days 0, 14, 28, 42 and 56 post-immunization). Geometric mean titer (GMT) values for 
BVDV neutralizing antibodies were substantially higher in blood sera of calves receiving the inactivated 
monovalent vaccine. The immune response developed more rapidly in calves immunized with the 
monovalent vaccine. 
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INTRODUCTION 
 
Bovine virus diarrhea virus (BVDV) is a member of the 
genus Pestivirus within the family Flaviviridae. BVDV 
causes infections of domestic and wild ruminants 
worldwide and significant economic losses to the cattle 
industry (Baker, 1995; Brownlie, 1991). BVDV is 
classified into one of two biotypes, cytopathic (CP) or 
non-cytopathic (NCP). Based on antigenic and genetic 
properties, two genotypes of the causative virus have 
been identified, BVDV-1 and BVDV-2: BVDV-2 makes up 
about 50% of the isolates in North America, whereas 
BVDV-1 predominates throughout Europe, with more 
than 90% (Ridpath, 2005; Vilcek et al., 2005). BVDV-1 
and BVDV-2 genotypes have been further subdivided into 
subgenotypes BVDV-1a, BVDV-1b, BVDV-2a and  BVDV  
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2b in North America (Flores et al., 2002; Ridpath et al., 
2000). Another classification describes 11 genetic groups 
of BVDV (Vilcek 2001). The major economic losses due 
to BVDV infection include reduced fertility, abortions and 
the generation of persistent viremic calves, which can 
develop fatal “mucosal disease” (Bielefeldt, 1995; 
Brownlie, 1990). Persistently infected (PI) live long-term 
virus carriers play the key role in BVDV epidemiology. 
Control of BVDV infection/diseases includes both: 1) 
biosecurity to prevent entry of PI animals into the herd by 
testing cattle for BVDV, and 2) vaccines as part of routine 
immunization programs. These viral vaccines may be 
modified live virus (MLV), inactivated or chemically 
altered live virus vaccines (Hjerpe, 1990). The disadvan-
tages of modified live BVDV-containing vaccines include 
the following: utmost care needed when using and 
handling this vaccine in order to prevent inactivation, 
possible contamination with other viruses (Moennig et al.,  
  
 
 
2005), probability of development of postvaccinal 
mucosal disease (Lambert, 1973), not recommended for 
pregnant animals (transplacental infections) due to 
insufficient reliability (Kelling, 1996), possible vaccine 
strain shedding and introduction of new BVDV strains into 
herds, and the development of immunosuppression as 
induced by the vaccinal strain of the virus (Roth and 
Kaeberle, 1983). 
The disadvantages associated with inactivated BVDV 
vaccines include: higher price, necessity of revaccination 
(Brock and Chase, 2000), a longer period required to 
develop immunity (Bolin, 1995), possible anaphylactic 
and local reactions at the vaccination site, shorter 
duration of immunity, and the immune response being 
directed only against certain antigen variants of the virus 
(Kelling, 1996; Bolin et al., 1991). The purpose of this 
study is to determine the ability of the experimental inacti-
vated vaccines containing BVDV imunogens to induce 
neutralizing antibodies to type 1 BVDV strains in 
vaccinated calves. Two different experimental vaccines 
(monovalent and polyvalent) were evaluated using 
detection of virus neutralizing antibodies, as a measure of 
their immunogenicity in calves. 
 
 
MATERIALS AND METHODS 
 
Animals 
 
Normal healthy beef calves (Simmental race) of mixed sex were 
used. The calves were 6 to 7 months of age. The vaccinated calves 
were subjected to cohabitation with the unvaccinated animals 
(control group) in order to determine the possible transmission of 
vaccine virus to unvaccinated animals. During the experiment, the 
calves were kept in a closed building, in free stalls, on slatted floor, 
under conditions common in intensive calf rearing. 
 
 
Vaccine preparation 
 
Monovalent inactivated vaccine - lot 251200. Reference CP strain 
NADL, infective titer log 10-6 TCID/0.1 ml (CVL Weybridge, 
provided by Dr. Georgina Ibata) was grown at the MDBK (Madin 
Darby bovine kidney) cell line. The suspension of the harvested 
NADL strain of BVDV was heated at 37°C and inactivated by 
adding ß-propiolactone (diluted in cold distilled water 1:1.000). The 
inactivation process was followed by rolling (IKA WERKE 200 
rpm/min-1) for 3 h at 37°C. The total inactivation of the BVD 
harvested virus was controlled in accordance with European 
Pharmacopoeia 5.0., monograph: Bovine diarrhoea vaccine 
(inactivated) No 01/2005:1952 (Tests, Inactivation, p. 734). The 
harvested inactivated virus was used in the volume sufficient for 10 
doses of vaccine and inoculated in two passages, each of which 
was observed for 10 days. No live virus was detected in the cell line 
during the test. The suspension of inactivated virus was stored at -
20°C (the volume of the inactivated virus sample was 65.25 ml). 
The pH of the suspension following inactivation was 4.57, and was 
adjusted to 7.4 using 1M NaOH (0.6 ml). The suspension was 
assayed for sterility using thioglycolate broth, nutrient agar, nutrient 
broth and Sabouraud broth incubated at 37 and 25°C for 14 days. 
The assay confirmed sterility of the above suspension. Merthiolate 
preservative (1:10.000 to 0.7 ml 1% v/v) was added to the 
inactivated virus sample. At a pH of 7.56, 21.7 ml of sterile 25% 
(AlOH)3 and 0.29 ml  of  sterile  20%  aqueous  solution  of saponin  
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(MERCK) were added at a ratio of 1:1.500 to suspension of the 
inactivated BVDV vaccine strain. The volume of the prepared 
monovalent vaccine against BVDV infection in cattle was 87.94 ml. 
The pH of the vaccine - lot 251200 was 8.07 (Cheerer HANA). 
Sterility assay of the prepared vaccine was conducted in the same 
manner as that of the suspension. 
The assays confirmed sterility of the vaccine sample. Polyvalent 
inactivated vaccine - lot 270700. Five cp BVDV strains were used 
for the preparation of the polyvalent inactivated vaccine: 
 
1) W1. - 162903, virus titer log 10-6 TCID/0.1 ml, 27 ml. 
2) W2. - 172984, virus titer log 10-5 TCID/0.1 ml, 30 ml. 
3) W3. – 173481, virus titer log 10-5 TCID/0.1 ml, 30 ml. 
4) W4. - 179725, virus titer log 10-5 TCID/0.1 ml, 30 ml. 
The strains are all BVDV type 1 isolated in the United Kingdom in 
the 1980s. Monoclonal antibody typing procedure reveals that they 
are quite distinct. 
5) Local BVDV field isolate, derived from a calf suffering from 
mucosal disease (MD) and identified by standard VN test, with virus 
titer log 10-5 TCID/0.1 ml, 30 ml. 
 
All five CP BVDV strains were cultivated at the MDBK cell line. The 
virus suspension was inactivated by adding ß-propiolactone (final 
concentration 1:1.000), which was followed by rolling (IKA WERKE 
200 rpm/min-1) for 3 h at 37°C. The pH of the suspension following 
inactivation was adjusted to 7.4 using 1M NaOH. Prior to virus 
inoculation, the MDBK cell line was checked for the presence of the 
BVD virus. The test was performed following the procedure 
European Pharmacopoeia 5.0., procedure named: Cell cultures for 
the production of veterinary vaccines No 01/2005:50204 chapter 
5.2.4.; p. 458/459 (detection of specified viruses), using fluorescein 
conjugated antibodies (BVD) with the presence of a positive control 
cell line. The MDBK cell line was negative for the BVD virus. The 
suspension was assayed for sterility using thioglycolate broth, 
nutrient agar, nutrient broth and Sabouraud broth incubated at 37 
and 25°C for 14 days. The assay confirmed sterility of the 
aforementioned suspension. Upon inactivation of the viral 
suspension, 1% merthiolate (final concentration 1:10.000) was 
added to the suspension. Inactivated antigens were adsorbed on 
sterile Al(OH)3 by adding 25% sterile adjuvant twice, which was 
followed by continuous rolling on a magnetic mixer. During the 
process, the vaccine suspension samples were made of 135 ml CP 
BVDV strains and 33.8 ml Al(OH)3 to obtain a volume of 173 ml. A 
total of 0.6 ml of the second adjuvant, saponin (MERCK, 20%) was 
added to the sample, making the final concentration in the vaccine 
of 1:1.500. The pH of the prepared vaccine - lot 270700 was 7.39. 
The sterility assay of the prepared vaccine was conducted in the 
same manner as that of the suspension. The assay confirmed 
sterility of the vaccine sample. 
 
 
Vaccine trials 
 
All 29 calves in vaccine trials were seronegative before the initial 
vaccination on day 0, as detected by the virus neutralization test.  
The calves were divided into three experimental groups. Group 1 
consisted of 10 male calves vaccinated twice (on days 0 and 28) 
subcutaneously (s/c) with 2 ml of the inactivated polyvalent vaccine 
per animal. 10 calves (7 males and 3 females) constituting Group 2 
were inoculated twice (on days 0 and 28) subcutaneously (s/c) with 
2 ml of the inactivated monovalent vaccine per animal. The control 
group (C) contained 9 unvaccinated female calves. 
 
 
Serum collection 
 
Blood sera were collected, frozen and stored at - 20°C until 
assayed for antibodies. The collection  of  the  blood  sera from  the  
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Table 1. Serum antibody titers to BVDV in the calves receiving the polyvalent vaccine (Group 1). 
 
Calf serial number VNT Ab titer  on day 0/GMT 
VNT Ab titer  on day 
14/GMT VNT Ab titer  on day 28/GMT VNT Ab titer  on day 42/GMT VNT Ab titer  on day 56/GMT 
1 0 0 0 1:16 4 1:32 5 
2 0 0 0 0 0 1:2 1 
3 0 0 0 1:16 4 1:4 2 
4 0 0 1:4 2 1:64 6 1:128 7 
5 0 0 0 1:32 5 1:32 5 
6 0 0 0 1:8 3 1:16 4 
7 0 0 0 1:16 4 1:16 4 
8 0 0 0 1:8 3 1:8 3 
9 0 0 0 1:32 5 1:32 5 
10 0 0 0 0 0 1:16 4 
GMTlog2 0 0 0.20 3.40 4.00 
 
 
 
calves of both Groups 1 and 2 was performed using 
standard procedure at bi-weekly intervals (on days 0, 14, 
28, 42 and 56 in the vaccine trial). Blood samples for 
serological testing were taken from the control calves on 
days 0 and 56 of the experiment. 
 
 
Virus neutralization test 
 
The collected blood sera were tested by virus neutrali-
zation test (VNT) in cell cultures using Nunclon plates. The 
virus used was CP strain NADL, virus titer log 10-6 
TCID/0.1 ml (CVL, Weybridge). Cell line: MDBK, Brescia. 
The samples of blood sera were inactivated for 30 min at 
56°C. Preliminary testing was performed using twofold 
dilutions of the blood sera of 1:2 through 1:1024. 25 µl of 
the blood sera was incubated with 25 µl 100 TCID50 BVDV 
CP strain NADL for 1 h at 37°C. Following incubation, 50 µl 
of MDBK cell suspension was added at a concentration of 
3 x 105 cells/ml. The inoculated cell line was incubated for 
4 days at 37°C, and neutralization of CP strain infectivity 
was detected by observation of viral cytopathology. On day 
4, all blood sera that exhibited neutralizing viral activity in 
the 1:8 solution were titrated to 1:1024. The endpoint 
dilution of the blood sera that completely neutralized the 
BVD virus and prevented the development of the 
cytopathogenic effect (CPE) was the specific virus-
neutralizing antibody titer of the  blood  sera  samples.  The 
results obtained herein were calculated by statistical 
methods as logarithms of the reciprocal of the serum 
dilution (log10) for VNT expressed as geometric mean titers 
(GMTlog2) as described earlier by Brugh (1978). 
 
 
RESULTS 
 
Prior to vaccination (on the first day of 
immunization), all animals in each of the three 
experimental groups were seronegative for BVDV. 
At the end of the immunization trial (on day 56), all 
calves of the control group were still seronegative. 
The samples of blood sera of the seronegative 
calves receiving the polyvalent inactivated vaccine 
(Group 1) were tested on the presence and titer of 
the antibodies to BVDV by a VNT and sum-
marized in Table 1. This study presents individual 
animals and their respective antibody titers to 
BVDV NADL strain on blood sera collection on 
days 0, 14, 28, 42 and 56. In all animals, no 
neutralization occurred on days 0 and 14 
(GMTlog2 = 0). At revaccination (conducted 28 
days after vaccination), one animal (1/10) from 
Group 1 tested  seropositive,  with  BVDV-specific 
antibody titers of 1:4. Eight of the ten (8/10) calves 
vaccinated with the polyvalent vaccine on day 0 
and revaccinated with same vaccine on day 28 
were positive for BVDV specific antibodies on day 
42 of blood sera collection. The antibody titers 
induced by the polyvalent vaccines ranged from 0 
to 1:64. At the end of the immunization trial (on 
day 56), all calves in Group 1 were seropositive. 
The specific antibody titers against BVDV in the 
blood sera were within the 1:2 to 1:128 range. 
From days 28 to 56 of the immunization trial, 
GMTlog2 values increased continuously (0.2, 3.40 
and 4.00). The antibody responses to CP NADL 
strain BVDV found in the blood sera of the 
seronegative calves receiving the monovalent 
vaccine (Group 2) were assessed by the VNT and 
summarized in Table 2. In all test animals, no 
neutralization occurred on days 0 and 14 
(GMTlog2 = 0). At revaccination, five animals 
(5/10) from Group 2 tested seropositive, with 
BVDV-specific antibody titers ranging from 0 to 
1:16. All of the ten calves vaccinated with the 
monovalent vaccine on day 0 and revaccinated 
with the same vaccine on day 28 showed a BVDV 
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Table 2. Serum antibody titers to BVDV in the calves receiving the monovalent vaccine (Group 2). 
 
Calf serial number VNT Ab titer  on day 0/GMT 
VNT Ab titer  on day 
14/GMT VNT Ab titer  on day 28/GMT VNT Ab titer  on day 42/GMT VNT Ab titer  on day 56/GMT 
1 0 0 0 0 1:32 5 1:32 5 
2 0 0 1:2 1 1:8 3 1:4 2 
3 0 0 0 0 1:512 9 1:128 7 
4 0 0 0 0 1:256 8 1:64 6 
5 0 0 1:4 2 1:256 8 1:64 6 
6 0 0 1:16 4 1:128 7 1:256 8 
7 0 0 1:4 2 1:128 7 1:128 7 
8 0 0 1:2 1 1:512 9 1:128 7 
9 0 0 0 0 1:256 8 1:256 8 
10 0 0 0 0 1:128 7 1:64 6 
GMTlog2 0 0 1.00 7.10 6.20 
 
 
 
specific antibody response on collection day 42. 
The antibody titers induced by the monovalent 
vaccine ranged from 1:8 to 1:512. At the end of 
the immunization trial (on day 56), all calves were 
seropositive. The specific antibody titers against 
BVDV in the blood sera obtained from Group 2 
animals ranged from 1:4 to 1:256. The GMTlog2 
values highly increased between 28 and 42 days 
– reaching their peak values of 1.00 to 7.10 log2) 
and slightly declined 56 days after vaccination 
(6.20 log2). 
Statistical evaluation of the results obtained 
included the initial formation of statistical base 
which composed of 3 variables - trial day, 
experimental group and log-transformed values of 
specific antibody titers to BVDV (GMTlog2) - that 
was used in an individual LSD test - the least 
significant difference test, performed by means of 
a commercial statistical software (SPS statistical 
software ver. 5.0). The LSD test results are given 
in tabular form (Table 3).  The geometric means 
titers (GMTlog2) for each treatment group were 
compared for significant differences between the 
vaccine groups (1 and 2) at given  dates  of  blood 
sera collection. The results on the log-transformed 
values of specific antibody titers to BVDV 
(GMTlog2) for the Groups 1 and 2 animals as 
analyzed by the LSD test suggest that no 
significant difference was found between Groups 
1 and 2 calves on day 28 post-vaccination, nor 
between days 42 and 56 in both Groups 1 and 2 
animals. Statistically very significant differences of 
up to 99% were recorded between all other 
groups (Table 3). 
 
 
DISSCUSION 
 
Regarding the mentioned hazards, research 
activities have become more focused on the 
development of effective inactivated vaccines. In 
our study we opted for inactivated (mono and 
polyvalent) vaccines due to their greater safety 
and ability to provide protection to cattle of almost 
all ages, bred for different purposes. Previously 
published observations (Howard et al., 1994) 
suggested that it is not necessary to use live 
avirulent    virus   to   achieve   protection   of   the 
respiratory tract and that immunity is not depen-
dent on a local immune response. Considering the 
large volume of literature available on this subject, 
the personal experience acquired during our 
research and the identified research tasks that are 
associated with testing the immunogenicity of 
mono and polyvalent vaccines against BVDV in 
beef cattle, special importance was given to 
adequate selection of BVDV immunogens and CP 
vaccinal strains. We opted for MDBK cell line 
because comparison of the five cell cultures for 
viral antigen production showed that four of the 
cell cultures (calf testis cells, nasal mucosa line, 
embryo lung cells and lung-wash cell line) yielded 
similar amounts of antigen while MDBK cells gave 
a titer of antigen that was about 16-fold higher 
than that of the other four (Howard et al., 1994). β-
Propiolacton was used for chemical inactivation 
which was in line with the O.I.E. recommendations 
(O.I.E., 2000: Manual of Standards for Diagnostic 
Tests and Vaccines, Chapter X.5., Bovine viral 
diarrhea). In order to stimulate a stronger immune 
response, Al(OH)3 was used as an adjuvant and 
saponin as the second adjuvant, according  to  the 
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Table 3. Values of specific antibody titers against BVDV in blood sera of the test animals as obtained by VNT 
method and analyzed by LSD test. 
 
Groups x  42 - II 56 - II 56 - I 42 - I 28 - II 28 - I 
28 - I 0.2 6.9** 6.0** 3.8** 3.2** 0.8ns / 
28 - II 1.0 6.1** 5.2** 3.0** 2.4** /  
42 - I 3.4 3.7** 2.8** 0.6ns /   
56 - I 4.0 3.1** 2.2** /    
56 - II 6.2 0.9ns /     
42 - II 7.1 /      
 
28 - I  = Trial day 28, experimental Group 1 56 - I = Trial day 56, experimental Group 1 
28 - II = Trial day 28, experimental Group 2 56 - II = Trial day 56, experimental Group 2 
42 - I  = Trial day 42, experimental Group 1 42 - II = Trial day 42, experimental Group 2 
 
ns
- non significant; **- p<0.01 - statistically very significant differences. 
 
 
 
modified method of Howard et al. (1994). 2 ml of the 
mono- and polyvalent vaccines used in this study were 
subcutaneously (s/c) administered to each test animal; 
whereas available literature data had previously reported 
the use of higher doses of similar inactivated vaccines to 
inoculate animals. The standard dose of inactivated 
vaccine prepared by Howard et al. (1994) was 4 ml. 
Describing the effectiveness of the BOVIDEC (C-VET) 
vaccine, Brownlie et al. (1995) reported that the vaccine 
dose administered was 4 ml per animal. The dose of 
inactivated vaccine developed from the “258” BVD CP 
strain isolated from a case of acute MD in a herd of 
young cows in Denmark was 3 ml (Meyling et al., 1985). 
Fulton et al. (1995) compared the geometric mean titer 
(GMTlog2) values of virus-neutralizing antibodies to 
BVDV in the animals immunized with four different com-
mercial types of vaccine. The GMTlog2 ratio for the test 
calves receiving either mono- or polyvalent inactivated 
vaccine against BVDV infection in this study was 5.00 on 
days 28, 2.08 on day 42, and 1.55 on day 56 of blood 
sera collection for serological testing. This result 
suggests that the GMTlog2 values obtained were higher 
in animals receiving the monovalent vaccine. It is the 
opinion of the present authors that the immune response 
of the vaccinated animals to a single BVDV strain was 
stimulated more easily than the polyclonal response to 
five strains of the same virus. However, the effect of 
possible interactions between the BVDV antigens that 
may have led to reduced immunogenicity of certain 
strains used in this study antigens or weaker 
immunogenicity of the same vaccine should not be 
eliminated from consideration. 
The results of this study comply with those of the 
following authors: Fulton and Burge (2001) reported that 
the highest virus-serum neutralizing antibody titer (after a 
single MLV dose or two doses of inactivated vaccine) 
was detected on day 42 following primo-vaccination. 
Brownlie  et  al.  (1995)   determined   that   the   humoral 
immune response to the first dose of inactivated vaccine 
was weaker, turning into a typical anamnestic response 
stimulated by the second dose involving a much faster 
increase in antibody concentrations and higher antibody 
titers than after the primo-inoculation. Bolin (1993) 
reported some data as regarding the testing of the 
protective capacity of inactivated vaccines in accordance 
with the United States Code of Federal Regulations 546-
547, 1990.  
The data suggested that the virus-neutralizing antibody 
titer should be >/= 8 in four out of five test calves, which 
can be achieved 14 or more days after revaccination. 
Even with this highly stringent regulation applied, the 
inactivated vaccines produced in this study conform to 
established standards. The vaccines used in this study 
gave satisfactory results with regard to the rate of 
development of the BVDV specific hummoral immune 
response in vaccinated animals. Highly significant 
differences were determined between Groups 1 and 2 in 
antibody titer level on days 42 and 56 of study. Although 
a small increase in antibody titer was observed during 
this period, very significant differences were determined 
in BVDV antibody specific titers depending on the type of 
vaccine used (monovalent or polyvalent).  
The results obtained suggest the necessity to conduct 
further investigations aimed at increasing the immuno-
genicity of the vaccines by using higher-quality antigens 
and adjuvants and defining optimum doses and 
immunogen inoculation methods for test animals. The 
need to induce long-lasting protection of animals against 
BVDV infections requires both the use of more 
immunogenic vaccines and conducting trials in artificial 
infestation of pre-vaccinated animals with virulent BVD 
strains to provide more long-lasting immunity. This would 
enable immunoprophylaxis not only for respiratory 
infections in cattle but also for in utero infections as the 
greatest concern to BVD/MD epidemiology and 
pathogenesis. 
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